Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

P16INK4A derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16 expressing tumors

A p16ink4, tumor technology, applied in the fields of peptide sources, specific peptides, antibody medical components, etc., can solve problems such as no therapeutic effect

Active Publication Date: 2015-08-12
UNIVERSITY OF HEIDELBERG
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Prophylactic HPV vaccination is already available, but no therapeutic effect has been shown in persons already infected (Hildesheim et al., 2007)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • P16INK4A derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16 expressing tumors
  • P16INK4A derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16 expressing tumors
  • P16INK4A derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16 expressing tumors

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0034] For the preparation of peptides showing a specific degree of identity, eg, genetic engineering can be used to introduce amino acid changes at specific positions in the cloned DNA sequence to identify regions important for peptide function. For example, site-directed mutagenesis or alanine scanning mutagenesis (introducing a single alanine mutation at each residue in the molecule) can be used (Cunningham and Wells, 1989). The resulting mutant molecules can then be tested for immunogenicity using the assays in the Examples.

[0035] Preferably, the variant is characterized by no more than 8 amino acids, more preferably no more than 6 amino acids, even more preferably no more than 4 amino acid substitutions, deletions and / or additions.

[0036] In raw p16 Ink4a - Fragments In fragments, at least 5 contiguous amino acids, preferably at least 10 contiguous amino acids, more preferably at least 15 contiguous amino acids, even more preferably at least 20 contiguous amino acid...

Embodiment 1

[0050] Targeting p16 in patients with HPV-associated neoplasia INK4a Peptide T cell reactivity

[0051] To evaluate whether patients with HPV-associated tumors increase strongly overexpressed p16 INK4a T cells against strongly overexpressed p16 INK4a To what extent T cells respond, the application allows detailed characterization of p16-targeted INK4a Different approaches to the immune response to antigens. Targeting p16 in cervical cancer patients INK4a The discovery of a spontaneous immune response demonstrates the immunogenicity of the general antigen as well as of the specific p16INK4a fragment and for immunization containing the p16INK4a fragment with expression of p16 INK4a patients with tumors provided rationale.

[0052] will come from 13 individuals with expression of p16 INK4a Peripheral blood mononuclear cells (PBMC) and p16 of women with high-grade cervical dysplasia (CIN2 / 3) INK4a Peptides (Table 1) were incubated with p16 by applying INK4a BrdU assay for ...

Embodiment 2

[0056] use p16 INK4a Peptides prime healthy donor T cells in vitro

[0057] Tests covering the entire p16 INK4a Amino acid sequence of seven long 25-35mer peptides (each with 7-13 amino acid overlap) to define p16 capable of inducing T cells secreting interferon gamma in healthy donors in vitro INK4a Fragments (Table 1).

[0058] Table 1 Seven overlapping p16s used in in vitro experiments INK4a peptide

[0059]

[0060] To show p16 INK4a Fragment stimulates healthy donor T cells to secrete interferon gamma in vitro and identifies most immunogenic p16 INK4a source of epitopes, to investigate whether T cells isolated from the peripheral blood of healthy donors could be detected by these p16 INK4a Peptide stimulation in vitro. When using individual p16 in so-called ELISpot experiments INK4a During peptide challenge, if p16 INK4a Peptides are able to induce specific T cell responses in cell culture experiments, and T cells secrete cytokines. In the ELISpot assay, cyto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Described are particular fragments of the cyclin-dependent kinase inhibitor p16 capable of increasing IFN-ϒ secretion of T cells or inducing proliferation of T cells and the use of said fragments for immunizing an individual against HPV-associated or other p16INK4a expressing carcinomas, preferably advanced carcinomas.

Description

technical field [0001] The present invention relates to cyclin-dependent kinase inhibitor p 16INK4a Specific fragments of and said fragments are used for immunization against expressing p16 INK4a Use in individuals with tumors. Background technique [0002] Millions of people around the world suffer from and die from cancer every year. These mortality rates have remained unchanged for many years despite intensive treatment research. Heretofore, patients with cancer often had to undergo cancer removal surgery or chemotherapy or radiation therapy. However, this is accompanied by very large side effects which then contribute to the mortality of patients with cancer. Interestingly, human papillomavirus (HPV) is associated with the development of more than 5% of all cancers (Parkin and Bray, 2006). Prophylactic HPV vaccination is already available, but no therapeutic effect has been shown in persons already infected (Hildesheim et al., 2007). Therefore, there is a need for ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00C07K14/435
CPCA61K38/00C07K14/4738A61K39/0011A61P37/04A61K39/4611A61K2239/59A61K39/464449A61K39/464838C07K14/435A61K39/001149
Inventor 马提亚·克洛尔米里亚姆·雷乌舍恩巴赫马格纳斯·万克内贝尔-多伊贝里茨
Owner UNIVERSITY OF HEIDELBERG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com